CoE for Neuroendocrine Tumors launched at Rela Hospital

September 20, 2022 13:30 IST | ANI Press Release
Tennis player James Blake
Noble Laureate Prof Ada.E Yonath launches Centre Of Excellence for Neuroendocrine Tumors at Rela Hospital

Chennai (Tamil Nadu) [India], September 20 (ANI/BusinessWire India): Rela Hospital, a Multi-Speciality Quaternary Care Hospital at Chrompet, Chennai launched the "Centre of Excellence for Neuroendocrine Tumors" to provide the highest standard of care and expertise to patients with Neuroendocrine Tumours in India. The centre was inaugurated by Noble Laureate, Prof Ada E.Yonath, who won the Nobel Prize in Chemistry in 2009 for her pioneering discoveries on the structure and function of ribosomes, the protein synthesizers in cells, other renowned researchers and scientists, in the presence of Dr Ilankumaran Kaliamoorthy, CEO, Rela Hospital.

Neuroendocrine tumors are cancers that begin in specialized cells called neuroendocrine cells. Neuroendocrine cells have traits similar to those of nerve cells and hormone-producing cells. A neuroendocrine tumor can start in almost any organ throughout the body, and it most commonly occurs in the gastrointestinal or GI tract, as well as the lungs and pancreas, appendix, small intestine and rectum. Diagnosis and treatment of neuroendocrine tumors depend on the type of tumor, its location, whether it produces excess hormones, how aggressive it is and whether it has spread to other parts of the body. The centre of excellence will have the experts from oncology, pathology, radiology, nuclear medicine, endocrinology, surgery, gastroenterology and nursing to enhance patient care.

For more information, click on the link below: (https://www.relainstitute.com/hospitals-chennai/institute-of-neuroendocrine-tumour)

Dr Ilankumaran Kaliamoorthy, CEO, Rela Hospital said, "We are extremely happy and honoured to have this centre launched by Prof. Ada. We at Rela Hospital, are developing this new speciality or centre of excellence to address this very rare tumor. With the help of the highly skilled Oncology team and a strong infrastructure, we thought this was the best time to launch this specialty centre and offer treatment to those suffering from this rare disease."

Dr C.S Mani, Senior Consultant- Surgical Oncology, Rela Hospital said, "Neuroendocrine is a special group of cells which is scattered all over the body from head to foot. Although they are present for a specific purpose, but they can unusually give rise to cancer of different types. In one end of the spectrum, it could sit and do nothing and in the other end it could be fatal. In recent times there has been an increase in the recognition of the tumor. A few renowned celebrities like Steve Jobs, Irfan Khan and Aretha Franklin were affected with this tumor. It is also increasing in incidence all over the world compared to last 10 to 15 years."

"Because of a wide variety of spectrum of this tumor, we thought it's high time that we give an additional impetus to the study of this tumor as well as prepare ourselves to the fundamental research on this rare type of cancer," added Dr C S Mani.

Prof Ada.E Yonath mentioned "I am very delighted to be here for the launch of this Neuroendocrine Tumor Centre at Rela Hospital. With the expertise and knowledge of the team of Oncologist here e, I am confident that patients with this life-threatening cancer will get the best treatment."

This story has been provided by BusinessWire India. ANI will not be responsible in any way for the content in this article. (ANI/BusinessWire India)


(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)


Dear Reader,

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor